245 - Clinical Trials That May Change Your Practice

Saturday, October 19, 2024

1:45 PM – 3:00 PM US PT

Location: Ballroom (West Hall B)

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Marina Nunez, MD,PhD

Infectious Diseases, HMB Clinical Director
Houston Methodist Specialty Group
Baytown, TX, United States
Ronald Washburn, MD

Professor of Internal Medicine, Section on Infectious Diseases
Atrium Health Wake Forest Baptist
Winston-Salem, NC, United States

Faculty(s)

Stephanie Fritz, MD, MSCI (she/her/hers)

Professor of Pediatrics
Pediatrics
Washington University School of Medicine
Saint Louis, MO, United States
Sanjeet Dadwal, MD, FACP, FIDSA (he/him/his)

Professor of Medicine & Chief, Division of Infectious Disease
Infectious Diseases
City of Hope National Medical Center
Duarte, CA, United States
Sarah Hammond, MD

Director of Hematology/Oncology Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Boston, MA, United States

Disclosure(s):

Marina Nunez: No financial relationships to disclose

Ronald Washburn, MD: ABBOTT LABS: Stocks/Bonds (Private Company) (Ongoing); AbbVie Inc: Stocks/Bonds (Private Company) (Ongoing); Pfizer, Inc.: Stocks/Bonds (Private Company) (Ongoing)

Stephanie A. Fritz, MD, MSCI: No financial relationships to disclose

Sanjeet S. Dadwal, MD, FACP, FIDSA: Ansun Biopharma Inc.: Grant/Research Support (Ongoing), Honoraria (Ongoing); AseptiScope Inc.: Advisor/Consultant (Ongoing), Stocks/Bonds (Private Company) (Ongoing); Astellas Pharma Inc.: Honoraria (Terminated, July 1, 2023); F2G Limited: Grant/Research Support (Ongoing); Karius, Inc: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Merck Sharp & Dohme Corporation: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Pfizer, Inc.: Grant/Research Support (Terminated, December 30, 2023); Takeda Pharmaceuticals U.S.A., Inc.: Honoraria (Terminated, June 30, 2023)

Sarah P. Hammond, MD: Cidara Therapeutics Inc.: Grant/Research Support (Ongoing); F. Hoffmann-La Roche Ltd.: Advisor/Consultant (Terminated, November 8, 2023); F2G: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); GSK: Grant/Research Support (Ongoing); Melinta Therapuetics: Advisor/Consultant (Terminated, December 12, 2023); Pfizer, Inc.: Advisor/Consultant (Terminated, September 22, 2023); Scynexis Inc.: Grant/Research Support (Ongoing)

Learning Objectives:

At the conclusion of this session, participants will be able to:

recognize the most impactful and clinically relevant bacterial clinical trials published within the past year;
recognize the most impactful and clinically relevant viral clinical trials published within the past year;
recognize the most impactful and clinically relevant fungal clinical trials published within the past year.

Presentations:

1:45 PM – 2:10 PM US PT

Clinical Trials in Bacterial Diseases that may Change your Practice
Speaker: Stephanie A. Fritz, MD, MSCI (she/her/hers) – Washington University School of Medicine
2:10 PM – 2:35 PM US PT

Clinical Trials in Viral Diseases that may Change your Practice
Speaker: Sanjeet S. Dadwal, MD, FACP, FIDSA (he/him/his) – City of Hope National Medical Center
2:35 PM – 3:00 PM US PT

Clinical Trials in Fungal Diseases that may Change your Practice
Speaker: Sarah P. Hammond, MD – Massachusetts General Hospital